Cardiol Therapeutics Inc Class A is seeing a positive shift in investor sentiment, as shown by its rising stock price.
Cardiol Therapeutics Inc Class A (CRDL.TO) is up today, gaining 1.59% to close at CA$2.55. This increase comes as the biotech sector continues to develop, especially in therapies for cardiovascular conditions.
Advertisement
Cardiol Therapeutics Inc Class A
CRDL.TO
CRDL.TO
Cardiol Therapeutics Inc Class A
WealthAwesomeAdvertisement
Market cap
$289.33M
52W high
$2.53
52W low
$1.23
1W change
+26.13%
Beta
0.47
Analyst Price Targets
Based on analyst covering CRDL
Wall Street analysts forecast CRDL stock price to rise 139.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+139.0% Upside
Current Price
C$2.51
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRDL's historical volatility
30-Day Vol
69.8%
Annualized
90-Day Vol
58.9%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$3.00
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$2.66 | C$2.09 – C$3.39 |
| 60 trading days | C$2.83 | C$2.01 – C$3.97 |
| 90 trading days | C$3.00 | C$1.98 – C$4.55 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Keep an eye on Cardiol Therapeutics as it navigates the complexities of the biotech landscape, particularly with its promising research in heart-related therapies.
1.59% Gain in Stock Price
The rise in Cardiol Therapeutics' stock price reflects growing investor interest in its innovative treatment solutions.
Bull case
The recent publication of Cardiol's Phase II MAvERIC study results in the Journal of the American Heart Association could boost investor confidence. This study highlights the effectiveness of its CardiolRx™ treatment for recurrent pericarditis.
Bear case
Despite today’s gains, Cardiol Therapeutics operates in a volatile sector and currently has no profit margin. This could pose risks for investors if future clinical trials don’t meet expectations.
Advertisement
Recent Developments
Cardiol Therapeutics has been making progress in the biotech field, particularly with its CardiolRx™ treatment aimed at easing symptoms of recurrent pericarditis. The publication of its Phase II study results marks a significant milestone that could strengthen its market position.
Market Reactions
Today's stock rise reflects a positive market reaction to Cardiol Therapeutics' ongoing research and development efforts. Investors seem optimistic about the company's future, especially following its recent successes in clinical trials.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
